Entest BioMedical Inc. (OTCBB: ENTB) announced it has obtained its first tumor specimen, a canine parathyroid tumor to be utilized in the development of Entest's immunotherapeutic cancer vaccine. According to Dr. Steven Josephs, lead cancer researcher for Entest, "Stem cells derived from tumors appear to be key components for creating an immunotherapeutic tumor vaccine. Inducing a patient's immune system to attack cancer stem cells may be a key step in complete elimination of the cancer."

Company Chairman David Koos said, "This is a major step in moving forward in the development of our immunotherapeutic cancer vaccine. Initially we will focus on treatment of cancer in canines, with the goal being eventually to extend our treatment model to humans. According to the National Canine Cancer Foundation, one out of every three dogs will develop cancer." The Company anticipates moving into human clinical trials once efficacy is established in the treatment of canines.

Koos also stated that, "Obtaining this specimen also represents a step forward towards our goal of jointly establishing a tumor bank and cancer research center with Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN), the company's largest shareholder."

About Entest BioMedical Inc.

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company is also involved in the development of medical devices (including stem cell extraction instrumentation).

Source
Bio-Matrix Scientific Group